Medicus Pharma seeks orphan drug status for SkinJect in Gorlin syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
April 17, 2026 7:30 AM EDTPHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the submission of an Orphan Drug Designation (ODD) application to the U.S. Food and Drug Administration for SkinJect® (D-MNA) for the treatment of basal cell carcinoma (BCC) in patients with Gorlin Syndrome, a rare genetic disorder characterized by the development of multiple, recurrent skin cancers.
The submission... More
